People living with chronic pain due to sickle cell disease (SCD) should be managed with a variety of pharmacologic and nonpharmacologic strategies, according to new guidelines released by the American Society of Hematology.
However, many modalities do not have strong evidence in the literature, according to the guidelines, and some common therapies, such as chronic monthly transfusion therapy, are not endorsed as a first-line treatment due to lack of evidence.
A dearth in the medical